Clinical Trials Directory

Trials / Completed

CompletedNCT06171438

Molecular Markers of Acute Kidney Injury in Elderly Deceased Donors

Status
Completed
Phase
Study type
Observational
Enrollment
200 (actual)
Sponsor
Institute for Clinical and Experimental Medicine · Other Government
Sex
All
Age
Healthy volunteers
Not accepted

Summary

Scoring systems that combine donor clinical and morphological parameters to predict outcome of kidney transplantation lack enough specificity to be generally accepted. Compare to classical histology, molecular assessment of renal tissue offers unbiased and technically robust approach. In this prospective 3-months' observational study procurement biopsies in 180 brain death donors will be performed. Using microarray which detect top differently regulated genes, conventional histology, urinary AKI biomarkers, renal function and clinical variables models predicting DGF and early graft scarring (IFTA, poor graft function) in recipients will be constructed. The associations of AKI in donors with distinct fibrosis atrophy and AKI molecular signals will be found. Molecular techniques and final models may help to improve the decision-making process for the acceptance of kidneys from marginal donors but more importantly, it may help clinicians to guide less toxic immunosuppression in identified problematic grafts.

Detailed description

The aim is to create a prediction model of early clinical outcome (delayed graft function) based on donor and recipient clinical variables, donor eGFR, urinary AKI biomarkers, histology (glomerulosclerosis, interstitial fibrosis, vascular changes) and top differently regulated genes found in microarray of wedge procurement donor biopsy. Construct a model capable to predict early renal allograft scarring (IFTA\>2), and impaired graft function (eGFR\<45 mL/min), as early as at 3 months. Describe renal molecular changes associated with established AKI in brain-death deceased donor and with aging.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTUrine BiomarkersBiomarkers of kidney damage in donors, such as neutrophil gelatinase-associated lipocalin (NGAL), N-acetyl-beta-D-glucosaminidase (NAG), beta2-microglobulin, alpha1-microglobulin, alpha2-macroglobulin and transferrin will be measured by ELISA.
DIAGNOSTIC_TESTGene expression profiling of donor kidneys by microarrayGene expression profiling of donor kidney biopsies using Affymetrix microarray platform (PrimeView Human Gene Expression Array).
DIAGNOSTIC_TESTGene expression profiling of recipient kidneys by microarrayGene expression profiling of donor kidney biopsies using Affymetrix microarray platform (PrimeView Human Gene Expression Array).

Timeline

Start date
2021-06-11
Primary completion
2022-12-01
Completion
2023-10-31
First posted
2023-12-14
Last updated
2023-12-14

Locations

1 site across 1 country: Czechia

Source: ClinicalTrials.gov record NCT06171438. Inclusion in this directory is not an endorsement.